Düsseldorf, Germany-based CUREosity, a MedTech company, announced on Monday that it has secured €3.8M in a growth financing round from existing and new investors.
The growth financing round saw participation from existing investor TechVision Fund (TVF), and the Belgian family office Nomainvest, alongside other new co-investors.
TVF, which specialises in investing in medical technology companies, has been supporting CUREosity since 2021.
The growth financing round also received support from the law firms ADVANT Beiten and Forvis Mazars.
The latest funding round will enable the German company to further advance its innovative solutions and expand its market presence.
Caesar van Heyningen, CEO of CUREosity, says, “The current successful course – consisting of scaling markets and high-quality updates of our therapy software – is strengthened by this financing. We plan to invest heavily in commercial expansion, incorporating tomorrow’s technological possibilities into our product roadmap today. With this financing round, we can ensure financial independence and sustainable business operations. A privilege – especially in tight market conditions.”
The birth of CUREosity
CUREO is based on the personal experiences of the founders — Thomas Saur, Stefan Arand, and Marco Faulhammer:
After a car accident in 2000, Thomas Saur’s infant son suffered from paraplegia. When searching for the best available care and rehabilitation, existing methods did not achieve the desired progress.
The two co-founders of CUREosity – Stefan Arand and Marco Faulhammer – experienced similar fates and challenges, which led them to the decision, to develop a new form of therapy that combines their therapeutic experiences and learnings with current technologies and neuroscientific findings.
Through many years of experience in 3D visualisation and the creation of application concepts in the IT and science sectors of working in this field, the founders bring profound technical know-how to the table.
The combination of technical skills, expertise in 3D visualisation, experience with Virtual Reality, and personal motivation from medical sufferings led to the foundation of CUREosity and the idea for CUREO.
CUREosity: Virtual Reality therapy through gamification
Led by Caesar van Heyningen, CUREosity is known for its Virtual Reality therapy system called CUREO for clinics and practices.
According to the company, CUREO’s advantages are evidence-based therapeutic success, sustainable relief of personnel, increased patient motivation, a wide range of applications, and easy and intuitive usability.
The 50 trainings in 7 modules can be used in physiotherapy, occupational therapy, and neuropsychology.
Currently, the software is used in 24 countries worldwide.
The investor
TechVision Fund (TVF) is an early-stage venture capital firm focused on investing in technology companies with the potential to transform major industries.
The company’s strategy revolves around early involvement, primarily targeting Seed-stage investments, with occasional initial investments in Series A.
The company focus spans SaaS/software, IoT, digital solutions, MedTech, biotech, new materials, and Greentech/cleantech.
Björn Lang, Partner at TVF says, “CUREOSITY solves the problem of the shortage of skilled workers in the field of therapy. Especially due to demographic change, smart solutions like CUREO are highly relevant to society. We look forward to participating in the solutions and successes in the future.”
01
How Leipzig became a hub for energy and medical tech startups with IRL and SpinLab support